Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies (Q33972690)

30 July 2017

1 reference

title

Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies (English)

1 reference

30 July 2017

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies (English)

1 reference

https://api.crossref.org/works/10.1016/S1083-8791(03)00287-8

stem cell transplantation

13 March 2024

main subject

Cytomegalovirus

0 references

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14506657

13 March 2024

1

Michael Boeckh

1 reference

30 July 2017

2

W Garrett Nichols

1 reference

Genovefa Anna Papanicolaou

30 July 2017

3

object named as

Genovefa Papanicolaou

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14506657

13 March 2024

5

John R. Wingard

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14506657

13 March 2024

author name string

Robert Rubin

4

1 reference

30 July 2017

John Zaia

6

1 reference

30 July 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14506657

13 March 2024

publication date

1 September 2003

1 reference

full work available at URL

30 July 2017

https://doi.org/10.1016/s1083-8791(03)00287-8

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14506657

https://api.elsevier.com/content/article/PII:S1083879103002878?httpAccept=text/xml

13 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1083-8791(03)00287-8

https://api.elsevier.com/content/article/PII:S1083879103002878?httpAccept=text/plain

13 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1083-8791(03)00287-8

Biology of Blood and Marrow Transplantation

13 March 2024

published in

1 reference

30 July 2017

9

1 reference

30 July 2017

543-558

1 reference

30 July 2017

9

1 reference

Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Beta-herpesvirus challenges in the transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Quantitation of cytomegalovirus: methodologic aspects and clinical applications.

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Long-term care after hematopoietic-cell transplantation in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

The dynamics of human cytomegalovirus replication in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Definitions of cytomegalovirus infection and disease in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Transferred herpes simplex virus immunity after stem-cell transplantation: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Improved monitoring of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation by an ultrasensitive plasma DNA PCR assay

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

CMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Human Cytomegalovirus (HCMV) Replication Dynamics in HCMV‐Naive and ‐Experienced Immunocompromised Hosts

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Recent advances in the therapy and prevention of CMV infections

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Cytomegalovirus (CMV)-Specific Intravenous Immunoglobulin for the Prevention of Primary CMV Infection and Disease after Marrow Transplant

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Clinical practice. Long-term care after hematopoietic-cell transplantation in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Clinical trials with CMV-specific T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Influence of antithymocyte globulin dose on outcome in cytomegalovirus‐seropositive recipients of partially T cell‐depleted stem cell grafts from matched‐unrelated donors

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2900287-8

7 January 2021

Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation

37

1 reference

https://api.crossref.org/works/10.1016/S1083-8791(03)00287-8

A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT)

13 March 2024

64

1 reference

https://api.crossref.org/works/10.1016/S1083-8791(03)00287-8

Prevention and treatment of cytomegalovirus infection after marrow transplantation

13 March 2024

66

1 reference

https://api.crossref.org/works/10.1016/S1083-8791(03)00287-8

Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients

13 March 2024

81

1 reference

https://api.crossref.org/works/10.1016/S1083-8791(03)00287-8

Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients

13 March 2024

88

1 reference

https://api.crossref.org/works/10.1016/S1083-8791(03)00287-8

13 March 2024

Identifiers

1 reference

30 July 2017

1 reference